Research and Markets: Green Rankings Business Report 2010-2011 - Exclusive & Quantitative Data Focusing on the Pharmaceuti

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of the "NEWSWEEK Green Rankings Business Report 2010-2011 Pharmaceuticals" report to their offering.

The Green Rankings Report is essential reading for everyone in CSR management, consultancy, marketing, communications, operations, investor relations and more. The report measures environmental impact, strategy, policy, management, reputation and overall performance.

Based on exclusive, quantitative data, the Pharmaceuticals Sector Report includes:

  • Sector analysis including detailed performance data about the companies in this sector, and each company's ranking relative to its peers.
  • Expanded information about the Newsweek Green Rankings 2010-2011 environmental reputation survey results.

The NEWSWEEK Green Rankings Business Report 2010-2011 - Full Report is also available.

Key Topics Covered:

  • Executive Summary
  • Methodology
  • The U.S. 500
  • The Global 100
  • The Industry
  • Reputation Survey

Companies Mentioned:

  • Abbott Laboratories
  • Allergan
  • Amgen
  • Biogen Idec
  • Bristol-Myers Squibb
  • Celgene
  • Eli Lilly
  • Forest Laboratories
  • Genzyme
  • Gilead Sciences
  • Hospira
  • Johnson & Johnson
  • Life Technologies
  • Merck
  • Mylan
  • Pfizer

For more information visit


Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United States  North America

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Environment



Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.